FirstLab will lead a project under the Eurostars-3 programme to deploy an ultrasound-based system that breaks down PFAS contamination at sites across Europe, according to a report by Chosunbiz.

The announcement places a Korean company at the head of a consortium inside one of Europe's largest public funding instruments for R&D-performing small and mid-sized enterprises. Eurostars, jointly funded by EUREKA member states and, through Horizon Europe, by the European Union, supports innovation projects led by SMEs that invest at least 10 percent of their turnover in research. Third-cycle participation, Eurostars-3, carries a total programme budget on the order of €1.2 billion, although the report does not specify the individual grant amount awarded to the FirstLab-led consortium.

Why PFAS destruction, and why now?

Per- and polyfluoroalkyl substances, a family of several thousand synthetic chemicals used in non-stick coatings, firefighting foams and industrial processes, resist conventional water treatment. Regulators are tightening limits. The European Chemicals Agency is considering a broad restriction proposal covering thousands of PFAS compounds, and the United States Environmental Protection Agency in 2024 set enforceable drinking-water limits of 4 parts per trillion for two of the most studied compounds, PFOA and PFOS. Incineration and activated-carbon capture remain costly, and carbon capture in particular shifts the problem to disposal of saturated media rather than eliminating the molecules.

Ultrasound-based destruction, typically sonolytic degradation, works by generating microscopic cavitation bubbles in contaminated water. When those bubbles collapse, they produce localized hot spots that cleave the strong carbon-fluorine bonds that make PFAS so persistent. The Chosunbiz report describes the FirstLab system in general terms as an ultrasound system that breaks PFAS, but it does not publish measured degradation rates, energy-per-litre figures, or the concentrations tested. Those specifications will determine whether the technology is competitive with electrochemical oxidation and plasma-based alternatives already in pilot deployment.

What the Eurostars-3 role means

Leading a Eurostars consortium carries obligations beyond the laboratory. The programme requires each project to be led by an R&D-performing SME, with partners from at least two EUREKA member countries, and funding flows through national agencies under standardized Eurostars rules rather than a single Brussels grant. For FirstLab, the role signals a European market entry strategy built on shared validation risk: partners typically contribute test sites, regulatory navigation and demonstration infrastructure that a single vendor would otherwise fund alone.

The Chosunbiz report names FirstLab as project lead but does not identify the consortium partners, the project budget, the deployment timeline or the target sites. Public Eurostars project records, once updated, should close those gaps; R&D managers evaluating ultrasonic PFAS treatment will want the consortium's validation protocol, sample volumes and baseline contaminant levels before drawing comparisons with incumbent technologies.

The commercial stakes

The PFAS treatment market is expanding quickly as liability pressure moves from chemical manufacturers downstream to water utilities, airports and industrial users. Ultrasound systems that can destroy PFAS on site, rather than concentrate them for off-site disposal, would shorten the compliance chain and reduce long-term operating costs. Whether FirstLab's system reaches that bar depends on scale-up data the consortium has yet to publish.

The coming project period, and the first field deployments under Eurostars-3, will show whether laboratory-scale bond cleavage translates into cost-effective destruction at European contamination sites.